Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preliminary study of two antiviral agents for hepatitis C genotype 1.

The New England journal of medicine - 19 Jan 2012

Lok Anna S, Gardiner David F, Lawitz Eric, Martorell Claudia, Everson Gregory T, Ghalib Reem, Reindollar Robert, Rustgi Vinod, McPhee Fiona, Wind-Rotolo Megan, Persson Anna, Zhu Kurt, Dimitrova Dessislava I, Eley Timothy, Guo Tong, Grasela Dennis M, Pasquinelli Claudio

Abstract excerpt

BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addition of multiple direct-acting antiviral agents to their treatment regimen. METHODS: This open-label, phase 2a study included an exploratory cohort of 21 patients with chronic HCV genotype 1 infection who had not had a response to previous therapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Pyrrolidines

Share to Recurrence

Share to Ribavirin

Share to Valine

Source

Identifiers

PMID: 22256805
DOI: 10.1056/NEJMoa1104430

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preliminary study of two antiviral agents for hepatitis C genotype 1.PMID 22256805Read ↗

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.Semantic proximity Read ↗

Real-World Experiences With a Direct-Acting Antiviral Agent for Patients With Hepatitis C Virus Infection.Semantic proximity Read ↗

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.Semantic proximity Read ↗

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.Semantic proximity Read ↗

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey.Semantic proximity Read ↗

Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.Semantic proximity Read ↗

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.Semantic proximity Read ↗

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.Semantic proximity Read ↗

Treatment of hepatitis C: a systematic review.Semantic proximity Read ↗

Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.Semantic proximity Read ↗

[Treatment guidelines for patients with genotype 1 chronic hepatitis C infection].Semantic proximity Read ↗

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.